Teladoc Health, Inc. (NYSE:TDOC) Q2 2022 Earnings Conference Call July 27, 2022 4:30 PM ET

Company Participants

Patrick Feeley - Vice President & Investor Relations

Jason Gorevic - Chief Executive Officer

Mala Murthy - Chief Financial Officer

Conference Call Participants

Ryan Daniels - William Blair

Lisa Gill - JPMorgan

Sandy Draper - Guggenheim Securities

Richard Close - Canaccord Genuity

Stephanie Davis - SVB Leerink

Sean Dodge - RBC

Charles Rhyee - Cowen

Daniel Grosslight - Citi

George Hill - Deutsche Bank

Jessica Tassan - Piper Sandler

A.J. Rice - Credit Suisse

Stan Berenshteyn - Wells Fargo

David Larsen - BTIG

Operator

Hello, and welcome to today's Teladoc Health Q2 Earnings Call. My name is Elliot, and I’ll be coordinating your call today. [Operator Instructions]

I would now like to hand over to Patrick Feeley, Vice President and Investor Relations. The floor is yours. Please go ahead.

Patrick Feeley

Thank you, and good afternoon. Today after the market closed, we issued a press release announcing our second quarter 2022 financial results. This press release and the accompanying slide presentation are available on the Investor Relations section of the teladochealth.com website.

On this call to discuss the results are Jason Gorevic, Chief Executive Officer; and Mala Murthy, Chief Financial Officer. During this call, we will also provide our third quarter and full year 2022 outlook, and our prepared remarks will be followed by a question-and-answer session.

Please note that we'll be discussing certain non-GAAP financial measures that we believe are important in evaluating Teladoc Health's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release that is posted on our website.

Also, please note that certain statements made during this call will be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause the actual results for Teladoc Health to differ materially from those expressed or implied on this call. For additional information, please refer to our cautionary statement in our press release and our filings with the SEC, all of which are available on our website.

I would now like to turn the call over to Jason.

Jason Gorevic

Thank you, Patrick. Good afternoon, and thank you for joining us. After the close today, Teladoc Health reported strong second quarter results with both revenue and adjusted EBITDA coming in above the midpoint of our guidance range.